-
公开(公告)号：EP4132932A1
公开(公告)日：2023-02-15
申请号：EP21783895.2
申请日：2021-04-07
IPC分类号： C07D487/10 , C07D471/10 , A61P35/02
-
公开(公告)号：EP3791185A1
公开(公告)日：2021-03-17
申请号：EP19725537.5
申请日：2019-05-07
发明人： ORDENTLICH, Peter , WANG, Lei , SANKOH, Serap , MEYERS, Michael
IPC分类号： G01N33/569 , G01N33/574
-
3.发明公开COMBINATION OF ER + LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER 审中-公开ER +配体和组蛋白去乙酰化酶抑制剂对癌症疗法相结合
公开(公告)号：EP2099443A1
公开(公告)日：2009-09-16
申请号：EP07854611.6
申请日：2007-11-09
IPC分类号： A61K31/165 , A61K31/44 , A61K31/335 , A61P35/00
CPC分类号： A61K31/165 , A61K31/335 , A61K31/44 , A61K45/06 , A61K2300/00
摘要： The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ERα+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.
-
公开(公告)号：EP4073100A1
公开(公告)日：2022-10-19
申请号：EP20899869.0
申请日：2020-12-09
IPC分类号： C07K14/71 , C07K16/28 , A61P37/06 , A61K39/395
-
公开(公告)号：EP3624848A1
公开(公告)日：2020-03-25
申请号：EP18733390.1
申请日：2018-05-18
发明人： ORDENTLICH, Peter , WANG, Lei
IPC分类号： A61K39/395 , A61K31/4406 , C07K16/28 , A61P35/00
-
公开(公告)号：EP2751267A4
公开(公告)日：2015-01-07
申请号：EP12827061
申请日：2012-08-31
发明人： GOODENOW ROBERT , ORDENTLICH PETER
IPC分类号： C12N15/09 , A61K31/4196 , A61K31/4406 , A61K31/5685 , A61K45/06
CPC分类号： A61K31/566 , A61K31/4196 , A61K31/4406 , A61K31/5685 , A61K45/06 , G01N33/4833 , G01N2800/52 , A61K2300/00
摘要： Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
摘要翻译： 本文描述了用于治疗受试者的乳腺癌的方法。 特别地，提供了用药物抑制剂和芳香酶抑制剂的组合治疗抗性转移性乳腺癌的方法。
-
公开(公告)号：EP4337329A1
公开(公告)日：2024-03-20
申请号：EP22808351.5
申请日：2022-05-12
IPC分类号： A61P35/00 , A61P35/02 , A61K31/555 , A61K31/551
-
公开(公告)号：EP3345002A1
公开(公告)日：2018-07-11
申请号：EP16843146.8
申请日：2016-09-02
发明人： ORDENTLICH, Peter
IPC分类号： G01N33/574 , G01N33/487 , C07C223/06 , C12N5/0786
CPC分类号： G01N33/57492 , A61K31/00 , A61K31/4406 , A61K31/5685 , A61K39/3955 , C07K16/2827 , C07K2317/24 , G01N33/5091 , G01N33/56972 , G01N2800/52
摘要： Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
-
公开(公告)号：EP2751267A1
公开(公告)日：2014-07-09
申请号：EP12827061.8
申请日：2012-08-31
IPC分类号： C12N15/09
CPC分类号： A61K31/566 , A61K31/4196 , A61K31/4406 , A61K31/5685 , A61K45/06 , A61P35/00 , G01N33/4833 , G01N2800/52 , A61K2300/00
摘要： Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
-
公开(公告)号：EP4337203A1
公开(公告)日：2024-03-20
申请号：EP22808443.0
申请日：2022-05-13
发明人： CACATIAN, Salvacion , KULKARNI, Santosh S. , SAMANTA, Swapan Kumar , REDDY, Virsinha Venkat , MCGEEHAN, Gerard M. , MILLER, William H. , CAMP, Nicholas Paul
IPC分类号： A61K31/438 , C07D471/10 , C07D487/10
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.014 秒)
